Brief: Urogen Pharma And MD Anderson Announce Strategic Research Collaboration
13/01/2021 16:01
Jan 13 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA AND MD ANDERSON ANNOUNCE STRATEGIC RESEARCH
COLLABORATION TO ADVANCE INVESTIGATIONAL TREATMENT FOR
HIGH-GRADE BLADDER CANCER
* UROGEN PHARMA LTD - COLLABORATION WILL FOCUS ON UGN-302 AS
AN
INVESTIGATIONAL TREATMENT FOR HIGH-GRADE NON-MUSCLE INVASIVE
BLADDER CANCER
Source text for Eikon: ID:nBw8Ls62Ba
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors